QIAGEN Plans To Achieve At Least 31% CER Adjusted Operating Income Margin In 2028; Plans To Return At Least $1B To Shareholders From 2024-2028

6/17/24 7:42:18 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $QGEN alert in real time by email

QIAGEN's leadership team will present the new 2028 targets, highlighting vision and strategy to sharpen its focus on growth pillars in the portfolio combined with commitments to solid profitable growth and disciplined capital allocation. This includes plans to return at least $1 billion to shareholders from 2024-2028, absent value-creating M&A opportunities, along with a high level of organic business investments.

QIAGEN has set a goal for at least $2 billion of combined annual sales in 2028 from its pillars amid plans for new product launches and important investments.

Get the next $QGEN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$QGEN

Date	Price Target	Rating	Analyst
10/17/2024	$49.00	Buy → Hold	HSBC Securities
6/27/2024	$50.00	Peer Perform → Outperform	Wolfe Research
12/19/2023	$44.00	Equal Weight	Wells Fargo
12/13/2023		Peer Perform	Wolfe Research
12/7/2023	$50.00	Neutral → Buy	Goldman
9/12/2023	$50.00	Outperform	Robert W. Baird
5/23/2023		Equal-Weight → Overweight	Morgan Stanley
10/18/2022		Equal-Weight	Morgan Stanley

More analyst ratings

$QGEN
Press Releases

Fastest customizable press release news feed in the world

QIAGEN collaborates with McGill University to advance microbiome research
Montreal, Canada, and Venlo, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced a collaboration with the McGill University Centre for Microbiome Research to support microbiome research activities and outcomes. The three-year partnership will further drive microbiome sciences – the study of a community of microorganisms that can be found living together in any environment, including the human body. It will focus on key areas such as DNA extraction from low microbial biomass samples and anaerobic culturing protocols. The collaboration is expected to strengthen QIAGEN's presence in microbiome research across North Amer
11/12/24 4:05:00 PM ET
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook
Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while results at constant exchanges rates (CER) of $502 million rose 6% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose three percentage points to 29.6% on benefits from the recent decision to discontinue the NeuMoDx system as well as broader efficiency gains that have improved profitability and freed up resources for targeted reinvestment. Adjusted diluted earnings per share (EPS) were $0
11/6/24 4:05:00 PM ET
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
Germantown, Maryland, and Venlo, the Netherlands, Nov. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use. This marks the fourth QIAstat-Dx syndromic test to receive U.S. regulatory clearance in 2024. Meningitis (inflammation of the membrane surrounding the brain and spinal cord) and encephalitis (inflammation within the brain) are medical emergencies that require immediate treatment. One in five cases of bacterial meningitis results in permanent complications, such as hearing loss, brain damage and seizures and witho
11/4/24 1:30:00 AM ET
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook
Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while results at constant exchanges rates (CER) of $502 million rose 6% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose three percentage points to 29.6% on benefits from the recent decision to discontinue the NeuMoDx system as well as broader efficiency gains that have improved profitability and freed up resources for targeted reinvestment. Adjusted diluted earnings per share (EPS) were $0
11/6/24 4:05:00 PM ET
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
QIAGEN N.V. to release results for Q3 2024 and hold webcast
Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect meService is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0448UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2492Conference ID:
10/10/24 7:41:37 AM ET
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
8/6/24 4:05:00 PM ET
$GSK
$MYGN
$PSNL
$QGEN
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Medical Specialities

$QGEN
Leadership Updates

Live Leadership Updates

Neogen Announces the Appointment of New Board Member
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
10/1/24 8:45:00 AM ET
$NEOG
$QGEN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Actym Therapeutics Appoints Chan Whiting as Chief Development Officer
BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer
11/11/21 9:00:00 AM ET
$QGEN
$TPST
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Quotient Limited Announces Appointment of Chief Commercial Officer
JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil
10/5/21 7:45:00 AM ET
$QGEN
$QTNT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances

$QGEN
Market Insights

Live Market Insights

QIAGEN Announces Partnership With The Snow Molecular Anthropology Lab At The University Of Montana In The Fields Of Human Identification And Forensics To Enhance The Identification Of Human Remains
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics.The partnership aims to provide forensic services for missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs) using DNA technologies such as next-generation sequencing (NGS) and forensic investigative genetic genealogy (FIGG).Within this long-term partnership, QIAGEN supports the Snow Molecular Anthropology Lab with a MiSeq FGx sequencing system, training, ForenSeq Kintelligence kits and the ForenSeq Kintelligence HT System.
7/8/24 4:06:23 PM ET
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wolfe Research Upgrades Qiagen to Outperform, Announces $50 Price Target
Wolfe Research analyst Doug Schenkel upgrades Qiagen (NYSE:QGEN) from Peer Perform to Outperform and announces $50 price target.
6/27/24 5:51:23 AM ET
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC), who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) results. Bristol Myers Squibb added adagrasib via its $5 billion Mirati Therapeutics Inc. deal. The approval is based on results from cohorts of the Phase 1/2 KRYSTAL-1 open-label study, which e
6/24/24 8:25:58 AM ET
$BMY
$QGEN
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

QIAGEN Plans To Achieve At Least 31% CER Adjusted Operating Income Margin In 2028; Plans To Return At Least $1B To Shareholders From 2024-2028

Chat with this insight

Recent Analyst Ratings for
$QGEN

$QGEN
SEC Filings

SEC Form 6-K filed by Qiagen N.V.

SEC Form 6-K filed by Qiagen N.V.

SEC Form 6-K filed by Qiagen N.V.

$QGEN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Qiagen N.V.

SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

$QGEN
Press Releases

Fastest customizable press release news feed in the world

QIAGEN collaborates with McGill University to advance microbiome research

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

$QGEN
Financials

Live finance-specific insights

$QGEN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Qiagen downgraded by HSBC Securities with a new price target

Qiagen upgraded by Wolfe Research with a new price target

Wells Fargo initiated coverage on Qiagen with a new price target

$QGEN
Leadership Updates

Live Leadership Updates

Neogen Announces the Appointment of New Board Member

Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

Quotient Limited Announces Appointment of Chief Commercial Officer

$QGEN
Market Insights

Live Market Insights

QIAGEN Announces Partnership With The Snow Molecular Anthropology Lab At The University Of Montana In The Fields Of Human Identification And Forensics To Enhance The Identification Of Human Remains

Wolfe Research Upgrades Qiagen to Outperform, Announces $50 Price Target

FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation

QIAGEN Plans To Achieve At Least 31% CER Adjusted Operating Income Margin In 2028; Plans To Return At Least $1B To Shareholders From 2024-2028

Chat with this insight

Recent Analyst Ratings for $QGEN

$QGEN SEC Filings

SEC Form 6-K filed by Qiagen N.V.

SEC Form 6-K filed by Qiagen N.V.

SEC Form 6-K filed by Qiagen N.V.

$QGEN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Qiagen N.V.

SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

$QGEN Press Releases

Fastest customizable press release news feed in the world

QIAGEN collaborates with McGill University to advance microbiome research

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

$QGEN Financials

Live finance-specific insights

$QGEN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Qiagen downgraded by HSBC Securities with a new price target

Qiagen upgraded by Wolfe Research with a new price target

Wells Fargo initiated coverage on Qiagen with a new price target

$QGEN Leadership Updates

Live Leadership Updates

Neogen Announces the Appointment of New Board Member

Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

Quotient Limited Announces Appointment of Chief Commercial Officer

$QGEN Market Insights

Live Market Insights

QIAGEN Announces Partnership With The Snow Molecular Anthropology Lab At The University Of Montana In The Fields Of Human Identification And Forensics To Enhance The Identification Of Human Remains

Wolfe Research Upgrades Qiagen to Outperform, Announces $50 Price Target

FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation

Recent Analyst Ratings for
$QGEN

$QGEN
SEC Filings

$QGEN
Large Ownership Changes

$QGEN
Press Releases

$QGEN
Financials

$QGEN
Analyst Ratings

$QGEN
Leadership Updates

$QGEN
Market Insights